More on subcutaneous #natalizumab for #MultipleSclerosis:
Final results from the SISTER study
@taneuroldisord.bsky.social
@taneuroldisord.bsky.socialMore on subcutaneous #natalizumab for #MultipleSclerosis:
Final results from the SISTER study
@taneuroldisord.bsky.socialWhat's the patient satisfaction of subcutaneous #natalizumab in patients with relapsing-remitting #MultipleSclerosis?
Chiara Zecca and colleagues report the results from the real-world, multicenter Swiss SATYSFACTION study:
journals.sagepub.com/doi/full/10....
